Shenzhen - Delayed Quote CNY

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ)

Compare
5.40 -0.08 (-1.46%)
At close: December 20 at 3:04:12 PM GMT+8
Loading Chart for 002099.SZ
DELL
  • Previous Close 5.48
  • Open 5.93
  • Bid 5.40 x --
  • Ask 5.41 x --
  • Day's Range 5.40 - 5.50
  • 52 Week Range 3.91 - 7.33
  • Volume 8,610,100
  • Avg. Volume 13,337,206
  • Market Cap (intraday) 8.741B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) --
  • EPS (TTM) -0.23
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 24, 2023
  • 1y Target Est --

Zhejiang Hisoar Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers antibiotics, cardiovascular products, hypoglycemic products, fine chemicals, dyes, intermediates, and other products, as well as clindamycin products. It also provides pharmaceutical, dyestuff, and other related services. The company was founded in 1966 and is based in Taizhou, China.

www.hisoar.com

2,612

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002099.SZ

View More

Performance Overview: 002099.SZ

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

002099.SZ
24.90%
SSE Composite Index
13.21%

1-Year Return

002099.SZ
20.12%
SSE Composite Index
14.86%

3-Year Return

002099.SZ
28.95%
SSE Composite Index
7.28%

5-Year Return

002099.SZ
19.02%
SSE Composite Index
11.63%

Compare To: 002099.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002099.SZ

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    8.74B

  • Enterprise Value

    8.38B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.97

  • Price/Book (mrq)

    1.60

  • Enterprise Value/Revenue

    4.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -19.05%

  • Return on Assets (ttm)

    -1.57%

  • Return on Equity (ttm)

    -6.50%

  • Revenue (ttm)

    1.94B

  • Net Income Avi to Common (ttm)

    -369.49M

  • Diluted EPS (ttm)

    -0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.48B

  • Total Debt/Equity (mrq)

    20.45%

  • Levered Free Cash Flow (ttm)

    347.11M

Research Analysis: 002099.SZ

View More

Company Insights: 002099.SZ

Research Reports: 002099.SZ

View More

People Also Watch